Advertisement Lupin and Merck Serono enter into strategic alliance - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Lupin and Merck Serono enter into strategic alliance

Lupin and Merck Serono have entered into a strategic partnership to support the latter to broaden its general medicines portfolio in emerging markets.

As part of this partnership, around 20 more new products will be added to the current portfolio, with first launches likely to happen in 2016.

With specific focus on cardiovascular and diabetes diseases, the alliance will cover countries such as Brazil, Mexico, Indonesia, Philippines and several countries in Africa and Central Eastern Europe as well as other countries in emerging markets.

This initiative will also help Merck Serono to widen its overall portfolio in core therapeutic areas of its General Medicine & Endocrinology franchise in selected countries in Latin America, Asia, Central Eastern Europe, and Africa.

Merck Serono global commercial head Elcin Ergun said: "The collaboration will significantly strengthen our portfolio and Merck Serono’s position as one of the major players in emerging markets, aiming to provide patients in these regions with better access to health."

Lupin will also take initiatives in areas such as the production, supply of product dossiers and finished product to Merck Serono, while the latter will be the marketing authorization holder for the products.

Financial details of the partnership remain undisclosed.